ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People’s Republic of China. ChromaDex Corporation is based in Irvine, California.

  • ChromaDex Achieves New Regulatory Milestones in the European Union & Australia
    on January 15, 2020 at 11:30 am

    LOS ANGELES, Jan. 15, 2020 -- ChromaDex Corp. (NASDAQ:CDXC) today announced regulatory authorizations to sell its patented nicotinamide riboside chloride (NR, or Niagen®) to.

  • First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
    on January 6, 2020 at 11:30 am

    ChromaDex Corp. (CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body.

  • Should ChromaDex (NASDAQ:CDXC) Be Disappointed With Their 69% Profit?
    on December 30, 2019 at 7:01 pm

    Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...

  • Hedge Funds Have Never Been More Bullish On ChromaDex Corporation (CDXC)
    on December 23, 2019 at 3:24 pm

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000

  • ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®
    on December 16, 2019 at 11:30 am

    ChromaDex Corp. (CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen® (nicotinamide riboside). The state of the science surrounding Niagen will be presented during the ChromaDex Scientific Advisory Board (SAB) annual meeting taking place Dec. 16-17 in Los Angeles, CA. Niagen is a unique form of vitamin B3 that helps to increase the body’s production of an important co-enzyme – nicotinamide adenine dinucleotide (NAD) – used to stimulate cellular energy production and support cellular repair.

  • ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide
    on December 11, 2019 at 11:30 am

    ChromaDex Corp. (CDXC) today announced the launch of Tru Niagen® Pro 500, the largest daily serving of its patented nicotinamide riboside (NR, or Niagen®) ingredient in the world. The product will be available exclusively through licensed healthcare practitioners in the United States, launching this weekend at the American Academy for Anti-Aging Medicine (A4M) Annual Meeting in Las Vegas, NV. “This new product will allow practitioners to provide a unique product to their patients who want more energy and improved cellular health,” says ChromaDex CEO Rob Fried.

  • ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand
    on December 5, 2019 at 11:30 am

    ChromaDex Corp. (CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until early 2023, which will now include Australia in its territory. On Monday, ChromaDex announced the receipt of approval of nicotinamide riboside chloride (NR, or Niagen®) as an ingredient in listed Complementary Medicines from the Australian Therapeutic Goods Administration (TGA). MHL is an established dietary supplement manufacturer and distributor in New Zealand with national and Australian distribution in both online and offline channels.

  • ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)
    on December 2, 2019 at 11:30 am

    ChromaDex Corp. (CDXC) today announced that it has received approval from the Australian Therapeutic Goods Administration (TGA) for its patented nicotinamide riboside chloride (NR) for use in listed complementary medicines. The listing indicates that ChromaDex has market exclusivity of NR through December 2, 2021. With this approval, ChromaDex will be listing their final product as a complementary medicine on the Australian Register of Therapeutic Goods (ARTG).

  • Edited Transcript of CDXC earnings conference call or presentation 12-Nov-19 9:30pm GMT
    on December 2, 2019 at 3:27 am

    Q3 2019 Chromadex Corp Earnings Call

  • European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food
    on November 20, 2019 at 11:30 am

    ChromaDex Corp. (CDXC) today announced that European Member States have voted in favor of listing Nicotinamide Riboside Chloride (NR) as a novel food ingredient at a daily serving of 300mg for the healthy adult population. This approval follows a positive opinion issued by the European Food Safety Authority (EFSA) in August 2019. “We are pleased to be extending our global footprint into Europe,” says ChromaDex CEO Rob Fried.

The world’s four leading regulatory bodies have backed our patented nicotinamide riboside (NR, or Niagen®) ingredient: the US, Canada, the EU, and Australia. We look forward to bringing @truniagen to the people of Europe and Australia. #healthyaging (

One of the most common questions we get at ChromaDex is: what’s the difference between #NMN and #NR? There’s so much misinformation going around on this topic, it's time for a tutorial.

Strength and grace in aging run parallel. With our attention affixed to #healthspan over #lifespan, we are able to offer exemplary cellular support. Step into your best self with Tru Niagen®.

Aging is an inevitable and enriching process. Society treats it as a problem to be tackled. When you focus on #healthspan over #lifespan, you put yourself at the helm of your own experience. As always, Chromadex aims for better aging.

Prioritizing health, Chromadex has always valued quality. What we offer is simple and achievable; nicotinamide riboside (NR) may help improve the #healthspan over #lifespan in adults, worldwide.

Load More...


What's Your Role?*



Company Description*



ChromaDex Corporation

10005 Muirlands Boulevard
Suite G
Irvine, CA 92618

+1 (949) 419-0288

January 2020
« Nov    

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account